2022
Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder
Rahman S, Lokeshwar S, Syed J, Javier-Desloges J, Press B, Choksi A, Rajwa P, Pradere B, Ploussard G, Kim J, Monaghan T, Renzulli J, Shariat S, Leapman M. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder. Urologic Oncology Seminars And Original Investigations 2022, 41: 107.e1-107.e8. PMID: 36481253, DOI: 10.1016/j.urolonc.2022.09.008.Peer-Reviewed Original ResearchConceptsVariant urothelial carcinomaNeoadjuvant chemotherapySubset of patientsUrothelial carcinomaOverall survivalPathologic responseRadical cystectomyNAC useClinical stage II diseaseHospital-based registry studyNeoadjuvant platinum-based chemotherapyPathologic lymph node positivityCox proportional hazards modelNational Cancer DatabaseStage II diseaseLymph node positivityPathologic complete responsePlatinum-based chemotherapyKaplan-Meier analysisMultivariable logistic regressionAnalysis of patientsBladder urothelial carcinomaProportional hazards modelCT2 diseasePathologic upstagingCorrelation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma
Chen X, Chen H, Lin R, Li Y, Guo Y, Chen Q, Zhang Y, Cai G, Hu M, Chen G. Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma. Journal Of Clinical Pathology 2022, 77: 61-67. PMID: 36319076, PMCID: PMC10804014, DOI: 10.1136/jcp-2021-207795.Peer-Reviewed Original ResearchPD-L1 expressionUrothelial carcinomaOverall survivalPD-L1Tumor cellsCell infiltrationInvasive frontPD-1/PD-L1 signal pathwayNon-small cell lung cancerOS of patientsInvasive bladder urothelial carcinomaPD-L1 groupIndependent prognostic factorT cell infiltrationAdvanced bladder cancerCell lung cancerImmune cell infiltrationMore T cellsFirst new drugT cell functionBladder urothelial carcinomaMeans of immunohistochemistryLymphocyte infiltrationPD-1Prognostic factorsTargeting bladder urothelial carcinoma with pHLIP-ICG and inhibition of urothelial cancer cell proliferation by pHLIP-amanitin
Moshnikova A, Golijanin B, Amin A, Doyle J, Kott O, Gershman B, DuPont M, Li Y, Lu X, Engelman D, Andreev O, Reshetnyak Y, Golijanin D. Targeting bladder urothelial carcinoma with pHLIP-ICG and inhibition of urothelial cancer cell proliferation by pHLIP-amanitin. Frontiers In Urology 2022, 2: 868919. PMID: 36439552, PMCID: PMC9691284, DOI: 10.3389/fruro.2022.868919.Peer-Reviewed Original ResearchWhite light cystoscopyCancer cell proliferationUrothelial cancer cellsMalignant lesionsUrothelial cancerBladder cancerCancer cellsSuperficial bladder cancerLaparoscopic radical cystectomyBladder urothelial carcinomaCell proliferationHr of treatmentRadical cystectomyIntravesical instillationBladder specimensUrothelial carcinomaUseful biomarkerNIRF imagingHuman bladderSitu casesDifferent subtypesHistopathological processingCystoscopyTumor cellsCancer
2018
CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma
Givechian KB, Garner C, Garban H, Rabizadeh S, Soon-Shiong P. CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. Oncotarget 2018, 9: 29743-29752. PMID: 30038717, PMCID: PMC6049856, DOI: 10.18632/oncotarget.25701.Peer-Reviewed Original ResearchBladder urothelial carcinomaPoor overall survivalUrothelial carcinomaOverall survivalBladder urothelial carcinoma patientsUrothelial carcinoma patientsPlatinum-based therapyMechanisms of chemoresistancePatient tumor samplesRepair genesSystemic chemotherapyFavorable survivalNucleotide excision repair genesWorse survivalCarcinoma patientsPoor survivalTherapeutic strategiesTherapy resistancePyrimidine synthesis pathwayRepair processClinical targetsTumor samplesPatientsCarcinomaDNA repair genes
2011
Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients With Urothelial Cancer
Tsao C, Moshier E, Seng S, Godbold J, Grossman S, Winston J, Oh W, Galsky M. Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients With Urothelial Cancer. Clinical Genitourinary Cancer 2011, 10: 15-20. PMID: 22130294, DOI: 10.1016/j.clgc.2011.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic AgentsCisplatinCreatinineEligibility DeterminationEthnicityFemaleFollow-Up StudiesGlomerular Filtration RateHumansKidney Failure, ChronicMaleMiddle AgedMuscle NeoplasmsNeoplasm InvasivenessPredictive Value of TestsRenal Insufficiency, ChronicRisk AssessmentSex FactorsUrinary Bladder NeoplasmsConceptsGlomerular filtration rateCKD-EPI formulaCKD-EPI equationCKD-EPIRenal functionCG formulaCisplatin-ineligibleCockroft-GaultMetastatic bladder urothelial carcinomaMedian glomerular filtration rateChronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equationCisplatin-based chemotherapyCisplatin-based therapyChemotherapy decision makingRenal function assessmentEstimate renal functionBladder urothelial carcinomaMount Sinai Medical CenterSinai Medical CenterCisplatin-eligibleMedian CrClUrothelial carcinomaCreatinine clearanceUrothelial cancerRetrospective study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply